Contradictory statements about the heterogeneity of BRAF mutation status in primary and metastatic melanomas exist.13,14,17–19,24–28 Most studies using IHC detection of BRAFV600E hardly found any evidence of intratumor heterogeneity and in general most BRAFV600E melanomas stained intensely and homogeneously.14,18,19,28,29 Wilmott et al13 reported a heterogeneous immunoreaction in 13 of 58 (22%) cases. This evidence concerns the gene BRAF and melanoma.